Do you have COVID-19? Join this study to help us find out if the drug Remdesivir can be given in the clinic!

We are inviting non-hospitalized patients with a recent COVID-19 infection to take part in this research study.

Open to people ages 12 years and up

• Willing and able to provide written informed consent, (individuals ≥ 18 years of age) or assent (individuals ≥ 12 and < 18 years of age) prior to performing study procedures. Individuals age ≥ 18 years may be enrolled with the consent of a legal representative where permitted according to local law and approved nationally and by the relevant institutional review board (IRB) or independent ethics committee (IEC). For individuals ≥ 12 and < 18 years of age, a parent or legal guardian must be willing and able to provide written informed consent prior to performing study procedures
• Either:
• Age ≥ 18 years (at all sites) or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law and approved nationally and by the relevant IRB or IEC with at least 1 pre-existing risk factor for progression to hospitalization (chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes, obesity (body mass index ≥ 30), immunocompromised, chronic mild or moderate kidney disease, chronic liver disease, current cancer, or sickle cell disease)
• OR aged ≥ 60 years
• SARS-CoV-2 infection confirmed by molecular diagnosis (nucleic acid (polymerase chain reaction (PCR) or antigen testing) ≤ 4 days prior to screening
• Presence of ≥ 1 symptom(s) consistent with COVID-19 for ≤ 7 days prior to randomization
• Not currently requiring hospitalization (hospitalization defined as ≥ 24 hours of acute care)

• Participation in any other clinical trial of an experimental treatment and prevention for COVID-19
• Prior hospitalization for COVID-19
• Treatment with other agents with actual or possible direct antiviral activity against SARS-CoV-2 or administration of any SARS-CoV-2 (or COVID-19) vaccine
• Requiring oxygen supplementation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.